Vonoprazan in the management of erosive oesophagitis and peptic ulcer-induced medication: a systematic review

Décio Chinzon; Joaquim Prado P. Moraes-Filho; Gerson Domingues; Juliana Leite Soares Guedes; Cláudia Yang Santos; Schlioma Zaterka

doi:10.5114/pg.2021.111401

eISSN: 1897-4317
ISSN: 1895-5770

Gastroenterology Review/Przegląd Gastroenterologiczny

Bieżący numer Archiwum Artykuły zaakceptowane O czasopiśmie Rada naukowa Bazy indeksacyjne Prenumerata Kontakt Zasady publikacji prac

Panel Redakcyjny

Zgłaszanie i recenzowanie prac online

NOWOŚĆ

Portal dla gastroenterologów!

www.egastroenterologia.pl

Wyszukiwanie

Zasady redakcyjne

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Otwarty dostęp

3/2022
vol. 17

Poleć ten artykuł:

Wyślij znajomemu

Skopiuj link:

Udostępnij:

streszczenie artykułu:

Artykuł przeglądowy

Vonoprazan in the management of erosive oesophagitis and peptic ulcer-induced medication: a systematic review

Décio Chinzon

¹

,

Joaquim Prado P. Moraes-Filho

¹

,

Gerson Domingues

²

,

Juliana Leite Soares Guedes

³

,

Cláudia Yang Santos

³

,

Schlioma Zaterka

¹

Department of Gastroenterology, University of Sao Paulo, Sao Paulo, Brazil

Department of Gastroenterology, State University of Rio de Janeiro, Rio de Janeiro, Brazil

Takeda Pharmaceuticals Brazil

Gastroenterology Rev 2022; 17 (3): 183–189

DOI: https://doi.org/10.5114/pg.2021.111401

Data publikacji online: 2021/12/08

Pełna treść artykułu Pobierz cytowanie

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Chinzon D, P. Moraes-Filho J, Domingues G, Soares Guedes J, Yang Santos C, Zaterka S. Vonoprazan in the management of erosive oesophagitis and peptic ulcer-induced medication: a systematic review. Gastroenterology Review/Przegląd Gastroenterologiczny. 2022;17(3):183-189. doi:10.5114/pg.2021.111401.

APA

Chinzon, D., P. Moraes-Filho, J., Domingues, G., Soares Guedes, J., Yang Santos, C.,  & Zaterka, S. (2022). Vonoprazan in the management of erosive oesophagitis and peptic ulcer-induced medication: a systematic review. Gastroenterology Review/Przegląd Gastroenterologiczny, 17(3), 183-189. https://doi.org/10.5114/pg.2021.111401

Chicago

Chinzon, Décio, Joaquim Prado P. Moraes-Filho, Gerson Domingues, Juliana Leite Soares Guedes, Cláudia Yang Santos,  and Schlioma Zaterka. 2022. "Vonoprazan in the management of erosive oesophagitis and peptic ulcer-induced medication: a systematic review". Gastroenterology Review/Przegląd Gastroenterologiczny 17 (3): 183-189. doi:10.5114/pg.2021.111401.

Harvard

Chinzon, D., P. Moraes-Filho, J., Domingues, G., Soares Guedes, J., Yang Santos, C.,  and Zaterka, S. (2022). Vonoprazan in the management of erosive oesophagitis and peptic ulcer-induced medication: a systematic review. Gastroenterology Review/Przegląd Gastroenterologiczny, 17(3), pp.183-189. https://doi.org/10.5114/pg.2021.111401

MLA

Chinzon, Décio et al. "Vonoprazan in the management of erosive oesophagitis and peptic ulcer-induced medication: a systematic review." Gastroenterology Review/Przegląd Gastroenterologiczny, vol. 17, no. 3, 2022, pp. 183-189. doi:10.5114/pg.2021.111401.

Vancouver

Chinzon D, P. Moraes-Filho J, Domingues G, Soares Guedes J, Yang Santos C, Zaterka S. Vonoprazan in the management of erosive oesophagitis and peptic ulcer-induced medication: a systematic review. Gastroenterology Review/Przegląd Gastroenterologiczny. 2022;17(3):183-189. doi:10.5114/pg.2021.111401.

Metryki PlumX:

Introduction
Vonoprazan has been found to promote a better antisecretory effect addressing acid-related diseases’ unmet needs.

Aim: To assess if vonoprazan effectively treats patients diagnosed with gastroesophageal reflux disease esophagitis or with peptic ulcers induced by chronic use of aspirin or non-steroidal anti-inflammatory drugs.

Material and methods
A literature search was conducted (April/2021) using Medline via PubMed, Cochrane library, Lilacs, Scielo, and Centre for Reviews and Dissemination electronic databases.

Results
We retrieved 55 titles. Of these, 13 met the eligibility criteria and were included in this review. Of these 13 articles, 4 were prospective cohort studies, 1 was a follow-up analysis of a preceding prospective study, 1 was a retrospective cohort study, and 6 were randomized clinical trials.

Conclusions
Our findings suggest that vonoprazan was effective and non-inferior to proton pump inhibitors in healing and maintaining healed reflux oesophagitis, leading to faster symptom relief. Vonoprazan may also be considered for preventing aspirin- or non-steroidal anti-inflammatory drug-related peptic ulcer recurrence.

Vonoprazan in the management of erosive oesophagitis and peptic ulcer-induced medication: a systematic review

Décio Chinzon 1 , Joaquim Prado P. Moraes-Filho 1 , Gerson Domingues 2 , Juliana Leite Soares Guedes 3 , Cláudia Yang Santos 3 , Schlioma Zaterka 1

Décio Chinzon

¹

,

Joaquim Prado P. Moraes-Filho

¹

,

Gerson Domingues

²

,

Juliana Leite Soares Guedes

³

,

Cláudia Yang Santos

³

,

Schlioma Zaterka

¹